摘要
研究尿激酶型纤溶酶原激活物 (uPA)及其特异受体 (uPA -R)和抑制物 (PAI - 1、PAI - 2 )在肺癌浸润转移中的作用。应用RIA分别对 6 7例经组织病理确诊的各期肺癌和 30例肺部相关炎症患者及 30名健康献血者进行了相应的检测。结果显示 ,小细胞肺癌Ⅱ期和Ⅲ期患者血浆中uPA、uPA -R、PAI - 1水平显著升高 (P <0 .0 0 1) ,而PAI - 2的水平逐渐降低 ;腺癌、鳞癌伴有浸润主支气管及肺门淋巴结者uPA、uPA -R与PAI - 1水平亦显著升高 (P <0 .0 0 1) ;周围型肺癌未见淋巴结受侵者uPA、uPA -R、PAI - 1与PAI - 2水平异常升高。uPA、uPA -R与PAI - 1在肺癌中水平明显升高 ,并与肺癌的浸润转移相关密切 ,可作为肿瘤患者早期诊断、预后评估的有力指标。
To study the relation of uPA, uPA-R, PAI-1 and PAI-2 with invasion and metastasis of lung cancer, the plasma specimens were collected from 67 patients with lung cancer, 30 patients with pneumonia and 30 healthy persons and were detcted by RIA.The results showed that the level of uPA, uPA-R and PAI-1 in small cell lung cancer in Ⅱ and Ⅲ stage was increased significantly(P<0.001) and the level of PAI-2 was reduced gradually.The level of uPA, uPA-R and PAI-1 in adenocarcinoma and squamous carcinoma accompanying with infiltration also was increased dramatcally(P<0.001).In peripheral type lung cancer without infiltration to lymph node, the level of uPA, uPA-R and PAI-1 was increased abnormally.uPA,uPA-R and PAI-1 were correlated closely with invision and metastasis of lung cancer and could be a indicator for early diagnosis and prognosis.
出处
《标记免疫分析与临床》
CAS
2004年第2期96-98,共3页
Labeled Immunoassays and Clinical Medicine
